Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBIT (2016 - 2025)

Haemonetics (HAE) has 17 years of EBIT data on record, last reported at $67.4 million in Q4 2025.

  • For Q4 2025, EBIT rose 14.17% year-over-year to $67.4 million; the TTM value through Dec 2025 reached $251.1 million, up 39.17%, while the annual FY2025 figure was $221.8 million, 34.53% up from the prior year.
  • EBIT reached $67.4 million in Q4 2025 per HAE's latest filing, up from $58.5 million in the prior quarter.
  • Across five years, EBIT topped out at $71.3 million in Q1 2025 and bottomed at -$21.2 million in Q2 2021.
  • Average EBIT over 5 years is $39.1 million, with a median of $41.5 million recorded in 2022.
  • Peak YoY movement for EBIT: tumbled 181.42% in 2021, then soared 2113.45% in 2022.
  • A 5-year view of EBIT shows it stood at $24.5 million in 2021, then surged by 76.58% to $43.3 million in 2022, then increased by 6.24% to $46.0 million in 2023, then increased by 28.39% to $59.0 million in 2024, then increased by 14.17% to $67.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $67.4 million in Q4 2025, $58.5 million in Q3 2025, and $53.9 million in Q2 2025.